Drug Safety
30 articles on Drug Safety, researched and written by the Shotlee Editorial Team from primary sources.
Peptides: Lab Finds Issues in 30% of Vials as FDA Panel Considers Looser Rules
Peptides are rapidly gaining traction for various health and wellness claims, but a recent lab analysis revealed significant quality control issues in a substantial percentage of tested vials. As the FDA panel prepares to discuss potentially easing restrictions, understanding the risks and the science behind these compounds is crucial.
7 min read
Compounded Ozempic and Zepbound Still Widely Available After Shortages End
Despite the FDA declaring an end to drug shortages for popular weight loss medications, a new study finds compounded versions remain easily accessible. Understanding the safety implications and regulatory landscape is crucial for patient health.
8 min read
Study Links GLP-1 Medications To Rare Vision Issue
New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.
6 min read
Ozempic Generics Recall: Why Cheap Semaglutide Copies Are Being Pulled
India's booming generic semaglutide market faces a credibility crisis as major manufacturers recall batches over quality concerns. Discover the implications for patient safety and treatment continuity.
9 min read
Ozempic & Wegovy Online: The Risky Rush to Bypass Doctor Consultations
The surge in GLP-1 medications for weight loss has led to a concerning trend: many online pharmacies are prescribing these powerful drugs with minimal to no doctor consultation, putting patients at significant risk.
6 min read
Ozempic & Wegovy for Kids? Doctor Warns of Dangers
While GLP-1 medications show promise for adult obesity, their use in children is raising significant concerns. A medical expert weighs in on the potential dangers and the critical need for specialist oversight.
7 min read
Beyond the Hype: Black Market Peptides Strain Vital Health Services
The booming trade in unregulated peptides for weight loss and body enhancement is placing unprecedented pressure on essential harm reduction services, originally established to combat the HIV epidemic. This article delves into the challenges, risks, and urgent needs arising from this new wave of drug use.
7 min read
Alli Weight Loss Pill: FDA Flags Serious Kidney Risks
The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.
8 min read
Alli's Kidney Risk: FDA Updates Label for Over-the-Counter Weight Loss Pill
The FDA has issued a critical update to the drug facts label for Alli, the only over-the-counter weight loss medication available in the U.S. The changes highlight rare but potentially severe kidney-related side effects, prompting new warnings for consumers.
7 min read
Beyond the Headlines: New GLP-1 Side Effects Uncovered on Reddit?
A groundbreaking study utilized AI to sift through over 400,000 Reddit posts, uncovering potential new side effects associated with popular GLP-1 medications such as Ozempic, Wegovy, and Mounjaro. This research highlights the growing role of real-world data in understanding medication safety.
8 min read
Ozempic Side Effects: AI Uncovers Hidden Symptoms on Reddit
Researchers at the University of Pennsylvania utilized artificial intelligence to analyze hundreds of thousands of Reddit posts, uncovering patient-reported side effects of GLP-1 medications that traditional clinical trials often overlook.
8 min read
Ozempic, Wegovy & Mounjaro: AI Uncovers New Patient-Reported Side Effects
New research leverages AI to sift through vast online discussions, identifying patient-reported side effects of popular GLP-1 medications that may not be fully captured in clinical trials.
7 min read
Ozempic, Mounjaro & More: AI Uncovers Hidden GLP-1 Side Effects
Popular GLP-1 medications such as semaglutide and tirzepatide are revolutionizing weight loss and diabetes management. A groundbreaking study using AI to analyze over 400,000 Reddit posts has shed light on potential side effects that may not be fully captured in traditional clinical trials, offering valuable insights for patients and healthcare providers.
7 min read
Wegovy and Eye Stroke Risk: What You Need to Know
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
7 min read
Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
7 min read
Social Media Reveals GLP-1 Side Effects Missed in Clinical Trials
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
4 min read
RFK Jr. Misrepresents Ex-FDA Officials in Push to Lift Peptide Ban
Health Secretary RFK Jr. is pushing to lift the FDA's ban on 19 peptides used in compounding pharmacies, claiming the decision was illegal with no safety signals. But former FDA officials, including Janet Woodcock, say he misrepresents their views amid documented risks like immune reactions and trial fatalities. As demand surges via influencers, recent illnesses highlight the stakes in this regulatory battle.
6 min read
Why US Patients Sue Ozempic Makers Over Gastroparesis, Vision Loss
Lawsuits against Ozempic manufacturer Novo Nordisk are exploding in the US, with patients alleging the company hid severe side effects like gastroparesis and sudden vision loss from semaglutide. Originally a type 2 diabetes drug, Ozempic's popularity as a weight loss shot has sparked debates on safety and marketing. Despite high demand, experts urge medical supervision to avoid serious risks.
5 min read
Biomea Fusion Reports Positive Phase II Data for Diabetes Drug Icovamenib
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
5 min read
GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia
Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.
7 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
5 min read
Taiwan FDA Warns: GLP-1 Weight Loss Drugs Like Ozempic Linked to 21 Adverse R...
Taiwan's Food and Drug Administration (FDA) has reported 21 cases of suspected adverse reactions to GLP-1 receptor agonists like Ozempic used for weight loss. Symptoms include gastrointestinal disorders, hypoglycemia, nausea, and more. Amid global concerns from US lawsuits and UK pancreatitis warnings, the FDA urges doctor-prescribed use only.
5 min read
FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
4 min read
FDA requests removal of suicide warning labels from GLP-1 weight-loss medications
The Food and Drug Administration announced on Tuesday its desire to remove suicide warning labels from GLP-1 weight-loss medications. A comprehensive review of 91 trials revealed no heightened risk of suicidal thoughts or behaviors among users compared to placebo groups. This change aligns the labels with those of diabetes equivalents from the same manufacturers.
2 min read
Cutaneous Reactions Rare Yet Differ Among GLP-1 Receptor Agonists
Research on FDA adverse event reports indicates that cutaneous side effects from GLP-1 receptor agonists occur infrequently, with variation depending on the drug. Semaglutide reported the highest rates, while dulaglutide had the lowest. Monitoring and awareness are key for patients using these medications.
3 min read
Wegovy Batches Withdrawn Upon Discovery of Hair in a Pre-Filled Syringe
Certain batches of Wegovy are being pulled from circulation because hair has been detected in pre-filled syringes. This action ensures patient safety and highlights the importance of quality control in pharmaceutical products. Consumers are advised to check for affected lots.
1 min read
Are Replicas of Ozempic and Wegovy Safe? Understanding Compounded GLP-1s
Compounded semaglutide medications are custom-made by compounding pharmacies, containing the active ingredient in Ozempic and Wegovy. However, they are not FDA-approved and carry potential risks. This article explains what you need to know about these alternatives.
12 min read
Safety Alert Released for Ozempic and Related GLP-1 Medications
A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
1 min read
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
1 min read
Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
4 min read